Partnering
Collaborators:
![](https://orlance.com/wp-content/uploads/2022/10/UWMed_logo.png)
![](https://orlance.com/wp-content/uploads/2022/10/NationalInst-Inf-logo.png)
IF YOU’RE A POTENTIAL PARTNER
Series A, corporate, foundation or government funding and collaboration, MACH-1 initial clinical programs for lead influenza and Covid-19 vaccine assets
DNA and mRNA clinical vaccine candidates in need of optimized formulation and delivery